Logo

Abbott Licenses DNA Probes to Ikonisys

Mar 22, 2005

NEW YORK, March 22 (GenomeWeb News) - Abbott has granted Ikonisys a worldwide license to manufacture and sell DNA probes for its Chromotest, a prenatal diagnostic for chromosomal abnormalities, the companies said today.

 

Ikonisys also obtained from Abbott rights to buy chromosome fluorescence in situ hybridization probes in the fields of pre-implantation genetic diagnosis and automated detection in amniocytes of FISH signals of "the most common chromosomal abnormalities."

Terms of the first agreement call for Ikonisys to pay Abbott an upfront, non-refundable license fee and royalties on commercialized kits. Terms of the second agreement were undisclosed. Ikonisys is based in New Haven, Conn.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.